^
Association details:
| Biomarker: | KRT19 elevation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Advanced pneumonic type of lung adenocarcinoma: survival predictors and treatment efficacy of the tumor
Published date:
08/06/2020
Excerpt:
The overall survival (OS) time was 10.4 months in TKI group, 8.8 months in the non-TKI group, and 2.1 months in the palliative care group. Patients with higher level of serum Cyfra21-1 had insignificantly shorter survival time compared to those with normal Cyfra21-1 (p = 0.067)...The comprehensive based TKI therapy provided improved OS vs the non-TKI therapy.
DOI:
https://doi.org/10.1177/0300891620947159
